Sanofi announces the publication in the New England Journal of Medicine (NEJM) of the results of a positive Phase III study of Dupixent (dupilumab) in the treatment of eosinophilic esophagitis in children aged 12 months to 11 years.

The majority of patients in this age group treated with Dupixent for eosinophilic esophagitis showed histological remission and sustained improvements for up to one year," says the healthcare group.

Data from this study prompted both the priority review granted to Dupixent by the U.S. FDA, and its approval for the treatment of eosinophilic esophagitis in children aged 12 months to 11 years and weighing at least 15 kg.

Copyright (c) 2024 CercleFinance.com. All rights reserved.